FXH vs IHI

Key Takeaways

• FXH employs a smart beta AlphaDEX strategy targeting healthcare providers and services with enhanced factor selection, offering broader diversification across 76 holdings, while IHI provides concentrated passive exposure to 47 medical device manufacturers.
• IHI boasts a lower expense ratio of 0.38% compared to FXH's 0.61%, potentially benefiting long-term cost efficiency for passive investors.
• FXH demonstrates stronger relative positioning in recent market cycles, with positive year-to-date returns amid healthcare provider resilience, contrasting IHI's sharper declines tied to medical device sector pressures.
• Both ETFs maintain solid liquidity profiles, though IHI's larger AUM exceeding $3 billion supports superior trading volume and tighter spreads.
• FXH's quarterly rebalancing via growth and value factors introduces moderate active risk, while IHI's market-cap weighting favors dominant large-cap device innovators.
• Sector momentum favors diversified healthcare plays like FXH amid regulatory and reimbursement uncertainties impacting devices.

Introduction

FXH and IHI offer compelling yet distinct pathways to healthcare sector exposure, making them relevant for investors navigating 2026's evolving market dynamics. While both reside within healthcare, FXH targets a broad spectrum of healthcare providers and services through a factor-enhanced approach, contrasting IHI's precise focus on U.S. medical device firms. They serve as alternatives for those seeking defensive stability (FXH) versus innovation-driven growth (IHI) amid aging demographics, AI integration in care delivery, and policy shifts. This ETF comparison highlights structural differences, aiding decisions on sector rotation and risk-adjusted positioning in a resilient yet volatile healthcare landscape.

First Trust Health Care AlphaDEX® Fund (FXH) Overview

The First Trust Health Care AlphaDEX® Fund (FXH) is a smart beta ETF that seeks to track the StrataQuant® Health Care Index. This index selects and weights stocks from the Russell 1000® Index's healthcare segment using the proprietary AlphaDEX® methodology, which scores companies on growth factors (e.g., sales growth, earnings momentum) and value factors (e.g., book value-to-price, price-to-sales). The top-ranked stocks form tiered equal-weighted tiers, aiming for potential outperformance versus traditional cap-weighted benchmarks. FXH holds approximately 76 stocks, providing diversified exposure primarily to healthcare providers, services, biotech, and pharmaceuticals. Top holdings include OGN (Organon & Co., ~3.8%), HUM (Humana Inc., ~3.1%), DVA (DaVita Inc., ~2.7%), ELV (Elevance Health Inc., ~2.7%), and MOH (Molina Healthcare Inc., ~2.5%), with the top 10 comprising about 25% of assets. Its expense ratio is 0.61%, and the fund rebalances quarterly to refresh factor exposures. Launched in 2007, FXH suits investors pursuing enhanced returns in healthcare through systematic factor tilts.

iShares U.S. Medical Devices ETF (IHI) Overview

The iShares U.S. Medical Devices ETF (IHI) is a passive ETF designed to track the Dow Jones U.S. Select Medical Equipment Index, comprising U.S. equities engaged in manufacturing and distributing medical devices such as MRI scanners, pacemakers, prosthetics, and X-ray machines. With around 47 holdings, it offers targeted exposure to this subsector, market-cap weighted toward leading innovators. Top holdings feature ISRG (Intuitive Surgical Inc., ~16.5%), ABT (Abbott Laboratories, ~16.1%), SYK (Stryker Corp., ~11.0%), EW (Edwards Lifesciences Corp., ~5.0%), and IDXX (IDEXX Laboratories Inc., ~4.7%), with the top 10 accounting for over 75% of assets—nearly 100% healthcare equipment. The expense ratio stands at 0.38%, lower than many peers, supporting cost-effective access. Inception in 2006, IHI appeals to those betting on medical technology advancements, though its concentration elevates single-subsector risk.

Industry and Thematic Backdrop

The healthcare sector endures as a defensive pillar amid macroeconomic uncertainty, propelled by aging populations, rising chronic disease prevalence, and AI-driven efficiencies in diagnostics and administration. Capital flows favor resilient subsectors, with recent inflows into broad healthcare ETFs signaling optimism. Catalysts include policy clarity on reimbursements, accelerated AI adoption for remote monitoring, and medical innovation in robotics and genomics. Medical devices (IHI) benefit from procedural volume growth in ambulatory settings and AI-enhanced tools, yet face headwinds from tightened pricing, supply chain volatility, and regulatory scrutiny on approvals. Healthcare providers (FXH core) grapple with margin pressures from labor shortages, uncompensated care, and Medicaid adjustments, offset by utilization rebounds in post-acute and home health. Risks encompass cybersecurity threats, workforce strains, and reimbursement cuts, underscoring the need for diversified exposure in this transformative environment.

Performance and Positioning Comparison

In recent weeks and months, FXH has exhibited relative strength, posting modest positive returns year-to-date amid broader healthcare rotation toward providers buoyed by steady utilization and demographic tailwinds. Over the trailing year, FXH's factor-driven selection has delivered mid-teens gains, outpacing IHI's declines linked to medical device valuation corrections and innovation execution delays. Three-year annualized figures show FXH holding steadier through cycles, benefiting from quarterly rebalancing that captures value opportunities in services. IHI, conversely, displays higher volatility from its concentrated large-cap tilt, underperforming in recent drawdowns tied to interest rate sensitivity and sector-specific probes. FXH's broader diversification tempers downside versus IHI's growth-beta exposure, positioning the former for stability amid shifting reimbursement dynamics and macro caution.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that empowers traders and investors to filter thousands of assets using customizable criteria like technical patterns, fundamentals, trends, volatility, and AI-generated signals. Users can scan by industry, market capitalization, price patterns, performance metrics, and indicators such as RSI (Relative Strength Index, measuring momentum) or moving averages. The platform identifies trade ideas, breakout candidates, and opportunities efficiently, surpassing manual screening. Explore it today to uncover healthcare ETF insights and beyond.

Tickeron AI Verdict

Tickeron’s AI currently favors FXH with moderate conviction (60-65% probability edge over IHI in the next cycle). This stems from FXH's superior recent trend consistency, broader diversification mitigating subsector risks, and factor methodology aligning with healthcare's value rotation amid reimbursement pressures. While IHI offers cost efficiency and innovation upside, its concentration amplifies volatility in uncertain policy environs.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations